Technical Analysis for BYSI - BeyondSpring, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Spinning Top | Other | -2.04% | |
Calm After Storm | Range Contraction | -2.04% | |
NR7 | Range Contraction | -2.04% | |
NR7-2 | Range Contraction | -2.04% | |
Narrow Range Bar | Range Contraction | -2.04% | |
Wide Bands | Range Expansion | -2.04% | |
Calm After Storm | Range Contraction | -0.69% | |
NR7 | Range Contraction | -0.69% |
Alert | Time |
---|---|
Down 5% | about 9 hours ago |
60 Minute Opening Range Breakdown | about 9 hours ago |
Outside Day | about 9 hours ago |
Fell Below Previous Day's Low | about 9 hours ago |
2x Volume Pace | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 04/18/2024
BeyondSpring, Inc. Description
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.0 |
52 Week Low | 0.6534 |
Average Volume | 222,952 |
200-Day Moving Average | 1.11 |
50-Day Moving Average | 1.47 |
20-Day Moving Average | 2.13 |
10-Day Moving Average | 2.99 |
Average True Range | 0.32 |
RSI (14) | 70.41 |
ADX | 48.53 |
+DI | 36.18 |
-DI | 10.31 |
Chandelier Exit (Long, 3 ATRs) | 3.04 |
Chandelier Exit (Short, 3 ATRs) | 2.01 |
Upper Bollinger Bands | 3.89 |
Lower Bollinger Band | 0.37 |
Percent B (%b) | 0.71 |
BandWidth | 165.33 |
MACD Line | 0.49 |
MACD Signal Line | 0.44 |
MACD Histogram | 0.0508 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.33 | ||||
Resistance 3 (R3) | 3.34 | 3.19 | 3.25 | ||
Resistance 2 (R2) | 3.19 | 3.08 | 3.19 | 3.23 | |
Resistance 1 (R1) | 3.04 | 3.01 | 2.96 | 3.03 | 3.20 |
Pivot Point | 2.89 | 2.89 | 2.86 | 2.89 | 2.89 |
Support 1 (S1) | 2.74 | 2.78 | 2.67 | 2.73 | 2.56 |
Support 2 (S2) | 2.59 | 2.71 | 2.59 | 2.53 | |
Support 3 (S3) | 2.44 | 2.59 | 2.51 | ||
Support 4 (S4) | 2.43 |